NASDAQ:ZYNE

Zynerba Pharmaceuticals Stock Forecast, Price & News

$5.47

-0.11 (-1.97 %)

(As of 06/18/2021 12:00 AM ET)

Add

Compare

Today's Range

$5.37

▼

$5.62

50-Day Range

$3.83

▼

$5.68

52-Week Range

$3.12

▼

$9.00

Volume1.20 million shs

Average Volume3.69 million shs

Market Capitalization$225.65 million

P/E RatioN/A

Dividend YieldN/A

Beta2.51

30 days | 90 days | 365 days | Advanced Chart

Receive ZYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Expected to Announce Earnings of -$0.20 Per Share
June 17, 2021 | americanbankingnews.com

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Short Interest Down 35.5% in May
June 14, 2021 | americanbankingnews.com

Zynerba Pharmaceuticals showcases Zygel study poster at annual SLEEP meeting
June 11, 2021 | proactiveinvestors.com

Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies
June 11, 2021 | finance.yahoo.com

Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
June 11, 2021 | finance.yahoo.com

Advancing Medical R&D for Cannabinoid Medicinal Uses Identifying Growing Number of Health Benefits
June 10, 2021 | marketwatch.com

Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
June 9, 2021 | finance.yahoo.com

Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Zynerba Pharmaceuticals, Inc. – ZYNE
June 7, 2021 | finance.yahoo.com

Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
June 4, 2021 | finance.yahoo.com

Traders Purchase High Volume of Zynerba Pharmaceuticals Call Options (NASDAQ:ZYNE)
June 3, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZYNE
Previous Symbol
CUSIPN/A
CIK1621443
Webwww.zynerba.com
Phone484-581-7505
Employees26
Year FoundedN/A

Sales & Book Value

Annual Sales$90,000.00
Price / Sales2,507.20
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.01 per share
Price / Book2.72

Profitability

EPS (Most Recent Fiscal Year)($1.90)
Net Income$-51,340,000.00
Net MarginsN/A
Return on Equity-63.26%
Return on Assets-54.05%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares41,252,000
Market Cap$225.65 million
Next Earnings Date8/9/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.22 out of 5 stars

Medical Sector

943rd out of 2,097 stocks

Pharmaceutical Preparations Industry

457th out of 831 stocks

3.4 Analyst's Opinion

Consensus Rating
Zynerba Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.65, Zynerba Pharmaceuticals has a forecasted upside of 149.5% from its current price of $5.47.
Amount of Analyst Coverage
Zynerba Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Zynerba Pharmaceuticals has received 634 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Zynerba Pharmaceuticals has received 559 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Zynerba Pharmaceuticals has received 53.14% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote “Outperform” if you believe ZYNE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZYNE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Zynerba Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Zynerba Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zynerba Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 11.10% of the stock of Zynerba Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 21.93% of the stock of Zynerba Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Zynerba Pharmaceuticals are expected to decrease in the coming year, from ($1.03) to ($1.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zynerba Pharmaceuticals is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zynerba Pharmaceuticals is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zynerba Pharmaceuticals has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

Is Zynerba Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Zynerba Pharmaceuticals stock.
View analyst ratings for Zynerba Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Zynerba Pharmaceuticals?

Wall Street analysts have given Zynerba Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zynerba Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals saw a decline in short interest in the month of May. As of May 28th, there was short interest totaling 2,330,000 shares, a decline of 35.5% from the May 13th total of 3,610,000 shares. Based on an average daily volume of 1,760,000 shares, the short-interest ratio is currently 1.3 days. Currently, 5.8% of the company's stock are sold short.
View Zynerba Pharmaceuticals' Short Interest.

When is Zynerba Pharmaceuticals' next earnings date?

Zynerba Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Zynerba Pharmaceuticals.

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) issued its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.20) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.05.
View Zynerba Pharmaceuticals' earnings history.

How has Zynerba Pharmaceuticals' stock price been impacted by Coronavirus?

Zynerba Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZYNE stock has increased by 40.6% and is now trading at $5.47.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ZYNE?

6 brokerages have issued 12 month target prices for Zynerba Pharmaceuticals' stock. Their forecasts range from $7.25 to $26.00. On average, they expect Zynerba Pharmaceuticals' share price to reach $13.65 in the next twelve months. This suggests a possible upside of 149.5% from the stock's current price.
View analysts' price targets for Zynerba Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the following people:

Mr. Armando Anido MBA, Chairman & CEO (Age 63, Pay $902.08k)
Ms. Terri B. Sebree, Pres (Age 63, Pay $686.79k)
Mr. James E. Fickenscher, CFO, VP of Corp. Devel. & Treasurer (Age 57, Pay $582.82k)
Ms. Suzanne M. Hanlon, Sec., VP & Gen. Counsel (Age 64)
Dr. Joseph Palumbo, Chief Medical Officer

Who are some of Zynerba Pharmaceuticals' key competitors?

Some companies that are related to Zynerba Pharmaceuticals include G1 Therapeutics (GTHX), Evelo Biosciences (EVLO), Epizyme (EPZM), Radius Health (RDUS), Nkarta (NKTX), OrganiGram (OGI), RAPT Therapeutics (RAPT), Zomedica (ZOM), Merus (MRUS), ADVANZ PHARMA (CXRXF), Praxis Precision Medicines (PRAX), Verastem (VSTM), Crinetics Pharmaceuticals (CRNX), Karyopharm Therapeutics (KPTI) and Affimed (AFMD).
View all of ZYNE's competitors.

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include AdvisorShares Investments LLC (3.73%), Davy Global Fund Management Ltd (1.75%), BlackRock Inc. (1.44%), Penserra Capital Management LLC (0.87%), D. E. Shaw & Co. Inc. (0.74%) and Mirae Asset Global Investments Co. Ltd. (0.71%).
View institutional ownership trends for Zynerba Pharmaceuticals.

Which major investors are selling Zynerba Pharmaceuticals stock?

ZYNE stock was sold by a variety of institutional investors in the last quarter, including Mirae Asset Global Investments Co. Ltd., JPMorgan Chase & Co., and Northern Trust Corp.
View insider buying and selling activity for Zynerba Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Zynerba Pharmaceuticals stock?

ZYNE stock was bought by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC, Davy Global Fund Management Ltd, D. E. Shaw & Co. Inc., Penserra Capital Management LLC, BlackRock Inc., Geode Capital Management LLC, HRT Financial LP, and Goldman Sachs Group Inc..
View insider buying and selling activity for Zynerba Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $5.47.

How much money does Zynerba Pharmaceuticals make?

Zynerba Pharmaceuticals has a market capitalization of $225.65 million and generates $90,000.00 in revenue each year. The company earns $-51,340,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.

How many employees does Zynerba Pharmaceuticals have?

Zynerba Pharmaceuticals employs 26 workers across the globe.

What is Zynerba Pharmaceuticals' official website?

The official website for Zynerba Pharmaceuticals is www.zynerba.com.

Where are Zynerba Pharmaceuticals' headquarters?

Zynerba Pharmaceuticals is headquartered at 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]

This page was last updated on 6/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here